ENGELHART-COMMODITIES
Engelhart Commodities Trading Partners, a global commodities trading business, is delighted to announce that it has agreed terms to acquire Trailstone, a global energy and technology company, from Riverstone.
Completion of the acquisition, which remains subject to regulatory approval, is expected to occur in Q3, 2024.
The deal is a significant event for both companies, as it represents a shared commitment to ensuring the success of the clean energy transition. The transaction not only strengthens their trading and technological capabilities, but also generates value through active support of a sustainable future.
Trailstone is a global leader in the provision of risk management and optimization services to the owners and operators of renewable power generation assets, by utilising its expertise, analytics and proprietary software. It is also active in trading power, natural gas and environmental products across North America, Europe and Asia.
The team at Trailstone has also built a successful physical natural gas client business in North America, which provides storage, transportation and supply capabilities to serve its customers' growing optimization and risk management requirements.
The acquisition will combine the resources and expertise of two successful businesses and enable them to leverage their joint capabilities to enhance trading performance, grow their customer business and play a leading role in decarbonising the world’s energy matrix.
The acquisition is a pivotal part of Engelhart’s strategic plan to strengthen its global power and gas trading platform and technology capabilities and generate value through active participation in the clean energy transition.
Huw Jenkins, Engelhart CEO, says the acquisition is a clear signal of Engelhart’s commitment to the clean energy transition:
“Agreeing terms to acquire Trailstone is an important event in Engelhart’s long term strategy to grow our energy trading platform and enhance our technological capability to play a leading role in the clean energy transition. We have been impressed by the Trailstone team’s innovation in the renewables trading sector and we believe the acquisition and merger will be highly complementary for both businesses.”
John Redpath, CEO, Trailstone, says he’s excited about the potential that this acquisition unlocks:
“The acquisition by Engelhart is a big moment for the future of Trailstone. The access to permanent capital, and the complementary nature of our two organizations means we can grow our renewables and power & natural gas businesses and create even more value as part of the clean energy transition. I am proud of what we've created at Trailstone over the last ten years, not because it was easy but because it was hard. I am even more positive and excited about the future as we move forward as one business. I've been in the energy markets for 35 years, and I think the most interesting years of my career are ahead as we build this combined business.”
FOR EDITORS
- The acquisition has been agreed but remains subject to regulatory approval.
- Latham & Watkins LLP acted as legal advisors to Riverstone and Trailstone. Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisers to Engelhart Commodities Trading Partners.
- Engelhart is a global commodity trading company founded in 2013, with ~180 staff across offices in London, Geneva, Houston, Stamford, Singapore, Shanghai and Beijing.
- Engelhart trades energy (power and gas, and oil) and is also active in agricultural/soft commodities, freight, and the innovative area of ‘risk premia’.
- Engelhart is owned by the same partner group that also controls BTG Pactual, the largest investment bank in Latin America.
- Trailstone is a global energy and technology trading company, operating at the intersection of renewable and conventional power. Trailstone provides a best-in-class service to help manage the intermittency of renewable power generation for asset owners, operators and grid infrastructure. Trailstone also offers tech-enabled risk management and asset management optimization solutions for renewables assets across Europe, Japan and the United States. Trailstone was founded in 2013 and has ~275 staff across offices in Europe, North America, and Japan, with its primary offices in London, Austin, and Berlin.
- Engelhart will acquire Trailstone from Riverstone LLC, the private equity fund that was its primary shareholder, subject to regulatory approval.
- Huw Jenkins will be the CEO of the new combined business; John Redpath will be Deputy CEO.
- No decision has yet been made on future naming and branding. For now, just use ‘Engelhart Commodities Trading Partners’, ‘Engelhart’ or ‘Trailstone’ or ‘the combined business’ to describe the relevant parties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609840553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
